Loading clinical trials...
Loading clinical trials...
Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)
Conditions
Interventions
optional ASA as comedication
placebo to ASA
+4 more
Locations
569
United States
Bronislava Shafran, MD PC
Phoenix, Arizona, United States
Westside Medical Associates of Los Angeles
Beverly Hills, California, United States
TriWest Research Associates, LLC
El Cajon, California, United States
University of California
Fresno, California, United States
Glendale Adventist Medical Center
Glendale, California, United States
Collaborative Neuroscience Network, LLC (CNS)
Long Beach, California, United States
Start Date
November 27, 2014
Primary Completion Date
August 14, 2018
Completion Date
August 14, 2018
Last Updated
September 6, 2019
NCT07371455
NCT06258538
NCT05093673
NCT07253181
NCT06870812
NCT04119544
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions